INTRODUCTION
Epilepsy is one of the most frequently occurring additional handicaps in people with learning disability 1, 2 . The risk of 'active' epilepsy in a non-learning disabled population has been estimated at 0.5% 3 . In those with a mild to moderate learning disability (IQ 35-70) this rises to 7%. In those with a severe or profound learning disability (IQ 34 and below) and a physical impairment the risk of active epilepsy has been estimated as high as 67% 2 . Associations between aggression/challenging behaviour, mental illness and epilepsy have also been described 4 .
It is clear therefore that the treatment of epilepsy forms an important aspect of patient management in the learning disabled population. Over the last decade there has been an expansion in the number of antiepileptic drugs (AEDs) available. Doctors must use these preparations in a rational and cost-effective way, maximizing benefit and minimizing adverse reactions.
There are currently approximately 300 mainly adult in-patients within the various specialized psychiatric and continuing care services at Northgate and Prudhoe NHS Trust. Many of these patients are receiving AEDs, some for reasons other than epilepsy (e.g. challenging behaviour, mood disorders). This audit project mainly considers the prescribing pattern of AEDs for epilepsy in the adult in-patients with learning disability. Data on the number and type of investigations for epilepsy were also collected.
The standards for this audit were difficult to establish given the dearth of large AED trials in this population. Standards were formulated which were partly extrapolated from studies performed in non-disabled adults with epilepsy. It is acknowledged that, given the wide inter-individual variation of this heterogeneous population, there may be many exceptions to any standards set.
Available evidence favours the use of monotherapy with variable but modest gains from the addition of a second AED in refractory cases. Figures quoted by studies are typically in the range of 20-30% reduction in seizure frequency by the addition of a second AED in refractory cases 5, 6 . There is currently no evidence that using more than two AEDs decreases seizure frequency in treatment resistant cases. However, the number of adverse reactions increases with the number of antiepileptic drugs prescribed 6, 7 . Given current available data, pharmacodynamic and pharmacokinetic interactions between two AEDs can be predicted with limited accuracy. However when using three or more antiepileptic drug medications such interactions are very complex, and in practice, impossible to foresee. In this population there are also potential interactions with psychotropic and other medications which the patient may be taking, further increasing the risks of adverse effects.
Sodium valproate and carbamazepine are recommended for initial first-line treatment of epilepsy in this population for several reasons:
1. Both drugs have been extensively used over the last 30 years and most of their side-effects are familiar.
2.
No new AED has been demonstrated to be superior to either drug in terms of efficacy 8, 9 .
3. Both drugs are substantially less expensive than the new generation of antiepileptic drugs 10 .
Earlier evidence favouring carbamazepine for partial seizures has not been borne out by more recent studies 11 . Smith's 1987 study of AED treatment 12 in US veterans has been criticized for being too specific to the treatment of seizures in older males. In addition it has been suggested that the study was biased in favour of carbamazepine 13 . Patients were excluded from Smith's study if they had failed to respond to carbamazepine previously. However such an exclusion for valproate was not relevant as this drug was not licensed for the treatment of epilepsy in the US at that time. Phenytoin, whilst still widely used first-line by some neurologists, is associated with a deterioration in cognitive functioning in patients with learning disabilities 14 . The standards for the audit are shown in Table 1 .
Patients with learning disability are more likely to experience multiple seizure types with earlier onset than non-disabled patients with epilepsy. In addition partial seizures may be more difficult to identify and control is less likely to be established 15, 16 . 
MATERIALS AND METHODS
The audit was carried out in May 2000, on 23 wards which housed adult in-patients with learning disabilities. All medication charts were examined to determine which patients were receiving antiepileptic drug medication. Patients receiving medication for epilepsy were identified by discussion with nursing staff and examination of the case notes. In cases where nursing staff were unsure about the reason for antiepileptic drug prescribing, inspection of past medical notes clarified the purpose of the medication. Once patients were identified as being treated for epilepsy (either active or in remission) with antiepileptic drugs their past medical and nursing notes were inspected and current drug regimen noted. Information was extracted from the case notes (Table 2) .
Whether a reduction in the number of, or dose of, AEDs could be attempted was estimated using the following criteria:
1. No change in seizure frequency following additional medication.
2. No change in seizure frequency following increase in dose.
3. Two or more AEDs being used at low dose.
RESULTS
Of 324 patients, 75 patients (23%) were identified as suffering from epilepsy. In addition to an ICD-10 17 diagnosis of mental retardation all but 10 patients had additional specifiers documented. The most common of these was behavioural problems (52 patients (69.3%)). In 13 cases (17.3%) patients had physical conditions strongly associated with epilepsy (e.g. tuberose sclerosis).
In 12 (16%) patients it was not possible to define seizure types. Forty-eight (64%) patients had been recorded as experiencing generalized tonic-clonic seizures in the past, although 32 of these also had other types of seizure recorded (almost always including complex partial). Thirty-seven had evidence of complex partial seizures. Only 18 (28.6%) patients experienced one single seizure type with the majority of patients suffering from multiple seizure types. There was evidence that eight patients (10.7%) had suffered from non-epileptiform attack disorder (NEADformerly referred to as 'pseudoseizures') as well as epilepsy. In addition, as a result of information obtained during this audit, one patient received a diagnosis of factitious epilepsy and his treatment was subsequently withdrawn.
There was a wide variation in seizure frequency; in 49 patients in whom seizures were still occurring and where seizure frequency could be identified with reasonable certainty the mean seizure frequency was 52.3 seizures per year (SD 122.5). These figures were distorted by a small number of patients (N = 6) having very frequent seizures (i.e. >100 per year). There was evidence that 19 patients (25.3%) had been seizure free for at least 1 year. In seven patients it was unclear whether seizures were still occurring.
By definition all 75 patients were on at least one AED. However in 11 patients it was not clear whether the current regimen was also serving a dual purpose of treating affective and/or behavioural disturbance. Table 3 shows the number of patients on mono, dual, triple or quadruple therapy. In total 12 patients (16%) were on three or more AEDs. The commonest form of dual therapy was a combination of sodium valproate and carbamazepine. Sixteen patients were prescribed this regimen. Of those 42 patients who were receiving two or more drugs there was evidence that 22 had not been tried on high dose monotherapy. The mean number of AEDs each patient was on was 1.7.
'New' (i.e. post-1985) antiepileptic drugs were being prescribed to 26 (34.7%) patients. Of these, six patients were receiving two new antiepileptic drugs whilst one patient was receiving a combination of three. Chart 1 depicts the relative popularity of the newer antiepileptic drugs being used, with lamotrigine being the most popular.
Initial first-line treatment could be determined from records in 61 patients. Twenty-four patients had been initially treated with carbamazepine, 11 with sodium valproate, four with phenytoin and 22 with either phenobarbitone or primidone. Those patients started on primidone or phenobarbitone all had been done so more than 15 years ago. Thus all patients who have been started on treatment in the last 5 years (where this could be identified) were commenced on either sodium valproate or carbamazepine first-line. a For the purposes of this audit 'status epilepticus' is defined as a seizure terminated after 5 min or more using as required medication in addition to the more usual definition of continuous seizure activity for 30 min or more. Dosing regimens varied widely; nine patients were on three times daily dosing of carbamazepine or sodium valproate and two patients on four divided doses of sodium valproate a day. The sustained release preparations of these two drugs were given twice daily even at total daily doses below 1500 mg.
Fifty-four patients (72%) were prescribed rectal diazepam 'as required' (PRN) for status epilepticus of which eight had actually received it on at least one occasion during the preceding 12 months. Six of these patients had been reported as experiencing status in the preceding 12 months and two patients had received the medication as a precautionary measure after seizures as they had a history of seizure clusters occurring. In addition to rectal diazepam prescribing for status, two patients had intranasal midazolam prescribed, one patient had intranasal midazolam and rectal diazepam prescribed and one patient had rectal paraldehyde prescribed in addition to rectal diazepam. There were no patients with a history of status epilepticus who did not have such 'as required' medication prescribed. Only nine (12%) patients were reported to be currently suffering from possible side-effects of AED treatment. These included 'weight gain' and hyponatraemia.
There was wide variation in the number and type of investigations performed. The average number of standard EEGs performed was three per patient (SD 2.9). Seven patients had no record of an EEG trace having been performed. In some cases this appeared to be due to the inability of the patient to cooperate with the investigation but it is likely that in the case of patients who had been admitted from outside the region previous EEG records may have been lost. One patient had 15 EEGs performed over a 45-year period. Eleven patients (14.7%) had received CT scans of the head with two having had failed attempts due to poor co-operation. Six had received MRIs and one had a failed attempt at an MRI scan due to poor cooperation. Four patients with partial seizures had received a CT scan whilst two had received an MRI. In addition three patients had received both an MRI and a CT scan for the investigation of partial seizures (including one patient in whom clear images could not be obtained). In three of these nine patients, imaging revealed potentially treatable conditions associated with seizures (the tubers of tuberose sclerosis, a subdural haematoma and focal mesial temporal sclerosis).
DISCUSSION
Forty-four per cent of patients were being maintained on monotherapy and only 16% of the studied population were on three or more AEDs. However of the patients who were receiving two or more drugs approximately half did not seem to have been tried on high dose monotherapy. Thirteen patients (17%) were identified as potentially benefiting from a reduction in the number of AEDs they were prescribed. Fifteen other patients were currently having a trial antiepileptic drug reduction. Reynolds and Shorvon 18 stressed the benefits of monotherapy claiming to have 72% of their non-disabled out-patients maintained on one AED. Similarly, other authors have highlighted the advantages of monotherapy and lower AED doses in patients with learning disability 15, 19 .
All patients with a history of status epilepticus had been prescribed rectal diazepam or an equivalent drug.
In recent years clinicians seem to be prescribing either sodium valproate or carbamazepine first-line, using new AEDs as second-line or adjunct treatment. Whilst some chronic patients are still being maintained on phenytoin and, occasionally, phenobarbitone, neither drug appears to have been introduced as a treatment for at least 5 years. Lamotrigine was found to be the most widely selected 'new' AED. The relative popularity of this AED compared to other of the more recently developed AEDs could be partly explained by the relatively lengthy amount of time it has been available for (since 1985) and by the perception by clinicians that it is generally well tolerated in patients, the main side-effect being an associated skin rash. This impression is supported by some evidence that lamotrigine may have a lower rate of, at least short-term, side-effects when compared to older AEDs 9 (e.g. Brodie et al. 8 ).
There was a lack of consistency in the use of investigations, even allowing for practical constraints. Whilst in this audit a single standard waking EEG was set as a standard, diagnostic accuracy can be improved by the use of sleep deprived or sedated EEGs. This raises sensitivity from around 50% to 80% from a single recording 20 . The ILAE has published guidelines on imaging, recommending MRI for those patients with evidence of partial seizures 21 . Only around 24% of patients with partial seizures received an MRI or CT scan although this may be due to sound practical reasons.
Approximately 75% of patients remained refractory to treatment. An identical proportion of refractory patients was found in a survey of adults with epilepsy and learning disabilities in the county of Leicester 16 . Also in agreement with this study was the high proportion of patients experiencing multiple seizure types, which similarly was more than half of the patients with epilepsy.
The findings of this study provides evidence that the standards set were appropriate and attainable in the majority of this patient group. The findings of the audit were presented at the appropriate meeting and the results circulated to the appropriate staff. A repeat of the audit will be performed to assess whether increased adherence to the standards has occurred in the mean-time and whether this results in an improvement in patient wellbeing.
